We are live on ! Find out more
IMUC.WS

ImmunoCellular Therapeutics Ltd.
IMUC.WS

Delisted

IMUC.WS was delisted on the 16th of October, 2018.

Back to rankings

4 hedge funds and large institutions have $54K invested in ImmunoCellular Therapeutics Ltd. in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

20% less funds holding

Funds holding: 5 → 4 (-1)

51% less capital invested

Capital invested by funds: $110K → $54K (-$56K)

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$240

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$365
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$44K – – –
SM
2
Sabby Management
Florida
$8K +$240 +5,000 +1%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$2K – – –
UBS Group
4
UBS Group
Switzerland
– -$365 -7,604 -73%

IMUC.WS Hedge Fund Activity: Q3 2017 in Review

4 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q3 2017, worth a combined $54K — down 51% from $110K a quarter earlier.

Fund positioning in IMUC.WS was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, adding an estimated $240. The largest seller was UBS Group, cutting an estimated $365.

  • 4 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q3 2017, down from 5 in Q2 2017.
  • Funds reported $54K of ImmunoCellular Therapeutics Ltd. stock for Q3 2017, down 51% quarter-over-quarter.
  • 0 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q3 2017 and 0 closed out.
  • The largest ImmunoCellular Therapeutics Ltd. buyer in Q3 2017 was Sabby Management, an estimated $240 added.
  • The largest ImmunoCellular Therapeutics Ltd. seller in Q3 2017 was UBS Group, an estimated $365 sold.

Based on aggregated 13F filings for Q3 2017.